# Aurobindo launches Adquey, enters US dermatology market 2026-10-01T19:51:49+00:00 | Business & Economy | Indian Opinion Desk Corroboration: 2 independent outlets Aurobindo Pharma subsidiary Acrotech Biopharma has launched Adquey (difamilast) in the US, the company's first novel dermatology drug. The non-steroidal topical ointment treats mild-to-moderate atopic dermatitis in adults and children aged two and above. The drug, licensed from Japan's Otsuka Pharmaceutical, competes with Arcutis Biotherapeutics' Zoryve and Pfizer's Eucrisa in a market estimated at about $1.3 billion for the 12 months ending July 2026. Brokerage Nuvama expects peak sales of around $300 million. Acrotech has set up a dedicated dermatology business unit for the launch. US sales account for about 40 per cent of Aurobindo's revenue. ## Indian Opinion Analysis The Economic Times and The Hindu both report the same core facts: Acrotech's launch of Adquey, the market size of $1.3 billion, and the licensing deal with Otsuka. The Economic Times adds business context absent from The Hindu: Nuvama's peak sales estimate of $300 million, the product's competition with Zoryve and Eucrisa, the company's FY27 revenue guidance of $2 billion, and its share price rise of over 1.2 per cent. The Hindu sticks to a shorter, straight-news summary of the launch and the new dermatology unit. The coverage is uniform in substance, The Economic Times simply provides a fuller commercial and market framing. ## Coverage Coverage: 2 sources, 2 neutral - economictimes.indiatimes.com (neutral report) Straight reporting with added business context and analyst forecasts - thehindu.com (neutral report) Concise wire-style summary of the launch announcement This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Tags: Acrotech Biopharma, Aurobindo Pharma, Otsuka Pharmaceutical, US FDA Canonical: https://indianopinion.org/aurobindo-launches-adquey-enters-us-dermatology-market/ License: Summary and commentary (c) Indian Opinion, reusable with attribution. Facts belong to the linked sources. Cite: https://indianopinion.org/aurobindo-launches-adquey-enters-us-dermatology-market/#story-in-brief How this brief was made: an AI model read the reports linked above and wrote this summary and analysis, which were published automatically. Published briefs are sampled every hour by an automated quality check; the editor verifies its findings and approves corrections, and corrected briefs carry a dated correction line. Stance labels are editorial classifications of how each outlet framed this story, assigned by the same model, not ratings of the outlets. We do no original reporting. Methodology: https://indianopinion.org/ai-use-policy/